{"id":"https://openalex.org/W2036601083","doi":"https://doi.org/10.1016/j.clgc.2014.12.019","title":"Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices","display_name":"Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices","alternate_titles":[],"publication_year":2015,"publication_date":"2015-01-09","ids":{"openalex":"https://openalex.org/W2036601083","doi":"https://doi.org/10.1016/j.clgc.2014.12.019","mag":"2036601083","pmid":"https://pubmed.ncbi.nlm.nih.gov/25743206"},"language":"en","primary_location":{"id":"doi:10.1016/j.clgc.2014.12.019","doi":"https://doi.org/10.1016/j.clgc.2014.12.019","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.clgc.2014.12.019","pdf_url":"http://www.clinical-genitourinary-cancer.com/article/S1558767315000026/pdf","source":{"id":"https://openalex.org/S71328803","display_name":"Clinical Genitourinary Cancer","issn_l":"1558-7673","issn":["1558-7673","1938-0682"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Genitourinary Cancer","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2036601083"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"http://www.clinical-genitourinary-cancer.com/article/S1558767315000026/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052069729","display_name":"Guru Sonpavde","orcid":"https://orcid.org/0000-0002-1010-9611","observed_orcids":["https://orcid.org/0000-0002-1010-9611"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]},{"id":"https://openalex.org/I4390039250","display_name":"UAB Medicine","ror":"https://ror.org/036554539","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4390039250"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guru Sonpavde","raw_affiliation_strings":["UAB Comprehensive Cancer Center, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UAB Comprehensive Cancer Center, Birmingham, AL","institution_ids":["https://openalex.org/I32389192","https://openalex.org/I4390039250"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007675629","display_name":"Menaka Bhor","orcid":"https://orcid.org/0000-0001-7014-4104","observed_orcids":["https://orcid.org/0000-0001-7014-4104"]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Menaka Bhor","raw_affiliation_strings":["McKesson Specialty Health and the US Oncology Network, The Woodlands, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"McKesson Specialty Health and the US Oncology Network, The Woodlands, TX","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112044924","display_name":"Daniel Hennessy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111804","display_name":"Sanofi (United States)","ror":"https://ror.org/027vj4x92","country_code":"US","type":"company","lineage":["https://openalex.org/I3018075036","https://openalex.org/I4210111804"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Hennessy","raw_affiliation_strings":["Sanofi US, Bridgewater, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi US, Bridgewater, NJ","institution_ids":["https://openalex.org/I4210111804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103797940","display_name":"Debajyoti Bhowmik","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Debajyoti Bhowmik","raw_affiliation_strings":["McKesson Specialty Health and the US Oncology Network, The Woodlands, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"McKesson Specialty Health and the US Oncology Network, The Woodlands, TX","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050901329","display_name":"Liji Shen","orcid":"https://orcid.org/0000-0003-0671-1041","observed_orcids":["https://orcid.org/0000-0003-0671-1041"]},"institutions":[{"id":"https://openalex.org/I4210111804","display_name":"Sanofi (United States)","ror":"https://ror.org/027vj4x92","country_code":"US","type":"company","lineage":["https://openalex.org/I3018075036","https://openalex.org/I4210111804"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liji Shen","raw_affiliation_strings":["Sanofi US, Bridgewater, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi US, Bridgewater, NJ","institution_ids":["https://openalex.org/I4210111804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013681510","display_name":"Leonardo Nicacio","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210111804","display_name":"Sanofi (United States)","ror":"https://ror.org/027vj4x92","country_code":"US","type":"company","lineage":["https://openalex.org/I3018075036","https://openalex.org/I4210111804"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leonardo Nicacio","raw_affiliation_strings":["Sanofi US, Bridgewater, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sanofi US, Bridgewater, NJ","institution_ids":["https://openalex.org/I4210111804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006351491","display_name":"Debra Rembert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Debra Rembert","raw_affiliation_strings":["McKesson Specialty Health and the US Oncology Network, The Woodlands, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"McKesson Specialty Health and the US Oncology Network, The Woodlands, TX","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028687337","display_name":"Mark Yap","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Yap","raw_affiliation_strings":["McKesson Specialty Health and the US Oncology Network, The Woodlands, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"McKesson Specialty Health and the US Oncology Network, The Woodlands, TX","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5007453606","display_name":"Ian D. Schnadig","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095874","display_name":"Compass Oncology","ror":"https://ror.org/00rq7v092","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210095874"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ian Schnadig","raw_affiliation_strings":["Compass Oncology, Portland, OR. Electronic address: ian.schnadig@usoncology.com","Compass Oncology, Portland, OR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Compass Oncology, Portland, OR. Electronic address: ian.schnadig@usoncology.com","institution_ids":["https://openalex.org/I4210095874"]},{"raw_affiliation_string":"Compass Oncology, Portland, OR","institution_ids":["https://openalex.org/I4210095874"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5007453606"],"corresponding_institution_ids":["https://openalex.org/I4210095874"],"apc_list":{"value":3530,"currency":"USD","value_usd":3530},"apc_paid":{"value":3530,"currency":"USD","value_usd":3530},"fwci":2.762,"has_fulltext":true,"cited_by_count":52,"citation_normalized_percentile":{"value":0.91194363,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"13","issue":"4","first_page":"309","last_page":"318"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10124","display_name":"Prostate Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-castration-resistant-prostate-cancer","display_name":"metastatic castration-resistant prostate cancer","score":0.949999988079071},{"id":"https://openalex.org/keywords/cabazitaxel","display_name":"cabazitaxel","score":0.925000011920929},{"id":"https://openalex.org/keywords/abiraterone-acetate","display_name":"abiraterone","score":1.0},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.9980000257492065},{"id":"https://openalex.org/keywords/treatment-sequencing","display_name":"treatment sequencing","score":0.847000002861023},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6679999828338623},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8140000104904175},{"id":"https://openalex.org/keywords/time-to-treatment-failure","display_name":"time to treatment failure","score":0.9940000176429749},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.7929999828338623},{"id":"https://openalex.org/keywords/third-line-therapy","display_name":"third-line therapy","score":0.828000009059906},{"id":"https://openalex.org/keywords/community-oncology-practice","display_name":"community oncology practice","score":0.6460000276565552},{"id":"https://openalex.org/keywords/treatment-patterns","display_name":"treatment patterns","score":0.6650000214576721},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.8360000252723694},{"id":"https://openalex.org/keywords/us-oncology-network","display_name":"US Oncology Network","score":0.7559999823570251},{"id":"https://openalex.org/keywords/androgen-deprivation-therapy","display_name":"androgen deprivation therapy","score":0.6129999756813049}],"concepts":[{"id":"https://openalex.org/C2778971682","wikidata":"https://www.wikidata.org/wiki/Q412963","display_name":"Cabazitaxel","level":5,"score":0.9503675103187561},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9426583051681519},{"id":"https://openalex.org/C2775832370","wikidata":"https://www.wikidata.org/wiki/Q27888393","display_name":"Abiraterone acetate","level":5,"score":0.900213360786438},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.8837114572525024},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.8087841272354126},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.7654974460601807},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6780530214309692},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6491071581840515},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.49586090445518494},{"id":"https://openalex.org/C2776421732","wikidata":"https://www.wikidata.org/wiki/Q27888393","display_name":"Abiraterone","level":5,"score":0.4913870394229889},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.4583958387374878},{"id":"https://openalex.org/C187960798","wikidata":"https://www.wikidata.org/wiki/Q7631152","display_name":"Subgroup analysis","level":3,"score":0.4166376292705536},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.40905943512916565},{"id":"https://openalex.org/C2777899217","wikidata":"https://www.wikidata.org/wiki/Q4759439","display_name":"Androgen deprivation therapy","level":4,"score":0.15405791997909546},{"id":"https://openalex.org/C61367390","wikidata":"https://www.wikidata.org/wiki/Q416601","display_name":"Androgen receptor","level":4,"score":0.12028440833091736}],"mesh":[{"descriptor_ui":"D000069501","descriptor_name":"Abiraterone Acetate","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000077143","descriptor_name":"Docetaxel","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001859","descriptor_name":"Bone Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001859","descriptor_name":"Bone Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D001859","descriptor_name":"Bone Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016016","descriptor_name":"Proportional Hazards Models","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D043823","descriptor_name":"Taxoids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D053208","descriptor_name":"Kaplan-Meier Estimate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064129","descriptor_name":"Prostatic Neoplasms, Castration-Resistant","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D064129","descriptor_name":"Prostatic Neoplasms, Castration-Resistant","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D064129","descriptor_name":"Prostatic Neoplasms, Castration-Resistant","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.clgc.2014.12.019","doi":"https://doi.org/10.1016/j.clgc.2014.12.019","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.clgc.2014.12.019","pdf_url":"http://www.clinical-genitourinary-cancer.com/article/S1558767315000026/pdf","source":{"id":"https://openalex.org/S71328803","display_name":"Clinical Genitourinary Cancer","issn_l":"1558-7673","issn":["1558-7673","1938-0682"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Genitourinary Cancer","raw_type":"journal-article"},{"id":"pmid:25743206","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25743206","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical genitourinary cancer","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1016/j.clgc.2014.12.019","doi":"https://doi.org/10.1016/j.clgc.2014.12.019","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.clgc.2014.12.019","pdf_url":"http://www.clinical-genitourinary-cancer.com/article/S1558767315000026/pdf","source":{"id":"https://openalex.org/S71328803","display_name":"Clinical Genitourinary Cancer","issn_l":"1558-7673","issn":["1558-7673","1938-0682"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Genitourinary Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2036601083.pdf","grobid_xml":"https://content.openalex.org/works/W2036601083.grobid-xml"},"referenced_works_count":22,"referenced_works":["https://openalex.org/W1884893528","https://openalex.org/W2036449946","https://openalex.org/W2078559150","https://openalex.org/W2080439368","https://openalex.org/W2103959341","https://openalex.org/W2110534364","https://openalex.org/W2117783793","https://openalex.org/W2120292596","https://openalex.org/W2121023961","https://openalex.org/W2123526148","https://openalex.org/W2137467802","https://openalex.org/W2141454098","https://openalex.org/W2148643283","https://openalex.org/W2165542862","https://openalex.org/W2166918329","https://openalex.org/W2170668585","https://openalex.org/W2244473630","https://openalex.org/W2278345104","https://openalex.org/W2466618799","https://openalex.org/W2582799504","https://openalex.org/W2999598241","https://openalex.org/W6773009007"],"related_works":["https://openalex.org/W2590442023","https://openalex.org/W2591048491","https://openalex.org/W1606511994","https://openalex.org/W2165606221","https://openalex.org/W2805401353","https://openalex.org/W2599742789","https://openalex.org/W2611624935","https://openalex.org/W2588377094","https://openalex.org/W2792598861","https://openalex.org/W1898921923"],"abstract_inverted_index":{"BACKGROUND:":[0],"Optimal":[1],"sequencing":[2],"of":[3,34,42,49,118,123,130,148,252,273,280],"cabazitaxel":[4],"(C)":[5],"and":[6,25,70,83,100,126,133,153,158,169,184,227,233],"abiraterone":[7],"acetate":[8],"(A)":[9],"after":[10,40,121],"docetaxel":[11],"(D)":[12],"for":[13,137,229,238,290],"metastatic":[14],"castration-resistant":[15],"prostate":[16],"cancer":[17],"(mCRPC)":[18],"is":[19],"unclear.":[20],"We":[21],"assessed":[22],"treatment":[23,67,103,154,275],"patterns":[24],"outcomes":[26],"in":[27,225,256,259,283,293],"patients":[28,62,163],"with":[29,63,68,74,167,201],"mCRPC":[30,64,292],"receiving":[31],"different":[32],"sequences":[33,198,206],"A":[35,274],"or":[36,38,76,78,89,95],"C,":[37],"both,":[39,79],"administration":[41,122],"D.":[43],"METHODS:":[44],"Retrospective":[45],"analysis":[46],"was":[47,235,276,287],"conducted":[48],"US":[50],"Oncology":[51],"Network":[52],"iKnowMed":[53],"(iKM)":[54],"electronic":[55],"health":[56],"record":[57],"(EHR)":[58],"data":[59],"to":[60,102,115,127],"assess":[61],"who":[65,164],"received":[66,87,174,178,182,187],"D":[69,124,168],"were":[71,106,165,199,220,254],"subsequently":[72],"treated":[73,166],"C":[75,253],"A,":[77],"between":[80],"April":[81],"2011":[82],"May":[84],"2012.":[85],"Patients":[86],"2":[88],"3":[90,281],"drugs:":[91],"DA,":[92,175,232],"DC,":[93,179],"DAC,":[94],"DCA.":[96],"Overall":[97],"survival":[98],"(OS)":[99],"time":[101],"failure":[104],"(TTF)":[105],"analyzed":[107],"by":[108],"the":[109,113,116,128,146,271,284],"Kaplan-Meier":[110],"method":[111],"from":[112],"start":[114],"end":[117,129],"second-line":[119],"therapy":[120,135],"(TTF1)":[125],"combined":[131],"second-":[132],"third-line":[134],"(TTF2)":[136],"3-drug":[138,197],"sequences.":[139],"Multivariable":[140],"Cox":[141],"proportional":[142],"hazard":[143],"models":[144],"evaluated":[145],"impact":[147],"baseline":[149],"clinical":[150],"prognostic":[151],"factors":[152],"sequence":[155,286],"on":[156],"OS":[157,203,226,234],"TTF.":[159],"RESULTS:":[160],"Of":[161],"350":[162],"subsequent":[170],"therapies,":[171],"183":[172],"(52.3%)":[173],"54":[176],"(15.4%)":[177],"77":[180],"(22.0%)":[181],"DCA,":[183],"36":[185],"(10.3%)":[186],"DAC.":[188],"In":[189],"a":[190],"multivariable":[191],"analysis,":[192],"adjusted":[193],"comparisons":[194],"suggested":[195],"that":[196],"associated":[200],"improved":[202],"versus":[204,231,240],"2-drug":[205],"(hazard":[207],"ratio":[208],"[HR],":[209],"0.21;":[210],"95%":[211,244],"confidence":[212],"interval":[213],"[CI],":[214],"0.092-0.476;":[215],"P":[216,247,267],"=":[217,248],".0002).":[218],"There":[219],"no":[221],"statistically":[222],"significant":[223],"differences":[224],"TTF":[228],"DC":[230],"significantly":[236],"greater":[237],"DCA":[239,257,285],"DAC":[241,260],"(HR,":[242],"0.13;":[243],"CI,":[245],"0.022-0.733;":[246],".0210).":[249],"More":[250],"cycles":[251],"administered":[255],"than":[258],"(median":[261],"6":[262],"vs.":[263],"4;":[264],"t":[265],"test":[266],"<":[268],".0001),":[269],"whereas":[270],"duration":[272],"similar.":[277],"CONCLUSION:":[278],"Administration":[279],"agents":[282],"more":[288],"optimal":[289],"treating":[291],"this":[294],"hypothesis-generating":[295],"study.":[296]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2036601083","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":13},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":7}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
